相关实验视频

Updated: Jun 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

在割抗性前列腺癌的恩扎胺和阿比拉和普雷迪尼索隆的剂量修改:PCa ENABLE研究的亚分析

Nobumichi Tanaka¹, Kouji Izumi², Yasushi Nakai¹

¹Department of Urology and Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Japan.

|September 20, 2024

概括

经过修改的阿比拉剂量显示,在割抵抗性前列腺癌患者中,前列腺特异抗原进展的时间有所改善. 恩扎胺剂量修改没有显著影响结果,两种药物的安全性概况相似.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.

背景情况:

头对头试验显示,恩扎胺 (ENZ) 和阿比拉 (ABI) 对割抵抗性前列腺癌 (CRPC) 提供了类似的生存益处.
减少ENZ和ABI的剂量可以维持雄激素受体 (AR) 信号抑制.
在ENABLE研究中,研究了在CRPC患者中修改剂量的ENZ和ABI.

研究的目的:

在CRPC患者中分析修改剂量的恩扎胺和阿比拉的疗效.
为了比较修改剂和标准剂量的ENZ和ABI之间的结果.
评估剂量修改对生存终点和安全性的影响.

主要方法:

在日本进行的研究人员发起的多中心随机对照试验.
患者接受了修改剂量 (ENZ ≤120 mg/天,ABI ≤750 mg/天) 或标准剂量 (ENZ 160 mg/天,ABI 1000 mg/天).
评估了生存终点,前列腺特异性抗原 (PSA) 反应率和安全性概况.

主要成果:

每组分析了92名患者;每个组中有16名患者接受了修改剂量.
与标准剂量相比,修改剂量显示PSA进展的时间 (TTPP) 和整体存活率 (OS) 显著改善 (TTPP的HR0.47,p=0.0379;OS的HR0.35,p=0.0162).
修改后的ABI显著改善了TTPP与标准ABI (HR 0.29,p=0.0248),但修改后的ENZ没有显示出显著的TTPP差异 (p=0.5366). 各组的不良事件发生率相似.

结论:

经过修改的阿比拉剂量与标准剂量相比,显示出优异的TTPP,为CRPC提供了潜在的治疗选择.
修改后的ABI提高疗效的机制尚不清楚,但AR信号抑制相当于标准剂量.
需要进一步研究以阐明CRPC的机制和优化治疗策略.

关键词:

一个是abiraterone.安卓素缺失疗法是一种安卓素缺乏疗法.割耐药的前列腺癌是什么剂量改变剂量改变酵素胺胺的使用方法

更多相关视频

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Dosage Regimen: Fixed Dose

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...